The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
T-CORE2401 trial: A randomized phase II trial of mFOLFOX6 plus cetuximab versus mFOLFOX6 plus bevacizumab as first-line treatment for right-sided, RAS/BRAF wild-type, low-methylated metastatic colon cancer.
 
Kota Ouchi
Honoraria - Asahi Kasei; Bristol-Myers Squibb Japan; Eisai; Lilly; Merck; MSD; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Research Funding - Hitachi (Inst); Riken Genesis (Inst)
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Ken Shimada
No Relationships to Disclose
 
Shin Takahashi
Honoraria - Asahi Kasei; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Merck; MSD; Ono Yakuhin; Taiho Pharmaceutical; Yakult Honsha
 
Kiichi Sugimoto
No Relationships to Disclose
 
Hiroshi Matsumoto
No Relationships to Disclose
 
Kenji Amagai
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst)
 
Takeshi Suto
No Relationships to Disclose
 
Yasuhiro Sakamoto
Honoraria - Astellas Pharma; Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; Daiichi-Sankyo Co. Ltd.; Lilly Japan; Merck Biopharma Japan Co.Ltd.; MSD K.K.; Taiho Pharmaceutical; Takeda
 
Akira Okita
Honoraria - Bristol Myers Squibb Company; Merck; Sumitomo Pharma Co., Ltd.; Taiho Pharmaceutical
 
Kazunori Otsuka
No Relationships to Disclose
 
Naoya Akazawa
No Relationships to Disclose
 
Taichi Isobe
Honoraria - Alexion Pharmaceuticals (I); Biogen (I); Chugai Pharma (I); Mitsubishi Tanabe Pharma (I); Novartis (I); Takeda (I)
 
Koji Fukuda
No Relationships to Disclose
 
Hideki Shimodaira
Speakers' Bureau - MSD; Taiho Pharmaceutical
Research Funding - Chugai Pharma
 
Yoshiaki Shindo
No Relationships to Disclose
 
Mizunori Yaegashi
Consulting or Advisory Role - Johnson&Johnson
Speakers' Bureau - Chugai Pharma; Covidien; Daiichi Sankyo; Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck; Taiho Pharmaceutical; Takeda; Terumo; Yahaba-cho
 
Hisato Kawakami
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; GlaxoSmithKline; Lilly Japan; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Daiichi Sankyo Co. Ltd.,
Research Funding - Bristol Myers Squibb Foundation (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - MEDICAL & BIOLOGICAL LABORATORIES CO., LTD for Integrin avß6 autoantibody assay kit in the diagnosis of irAE enteritis
 
Chikashi Ishioka
Honoraria - Asahi Kasei; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Incyte Japan; Kyowa Kirin International; Lilly Japan; m3.com; Merck; MSD; Nihon Servier; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Research Funding - Asahi Kasei (Inst); Ascent Pharmahealth (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Hitachi (Inst); Incyte (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka; Taiho Pharmaceutical (Inst)